PharmaCyte Biotech (NASDAQ:PMCB) Releases Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) posted its earnings results on Monday. The company reported ($0.10) earnings per share for the quarter, Zacks reports.

PharmaCyte Biotech Stock Performance

PharmaCyte Biotech stock opened at $1.58 on Tuesday. The firm has a 50-day moving average of $1.65 and a 200-day moving average of $1.70. The firm has a market cap of $10.85 million, a P/E ratio of 2.98 and a beta of -0.25. PharmaCyte Biotech has a 1-year low of $1.39 and a 1-year high of $2.58.

PharmaCyte Biotech Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.